Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jan;27(1):8-10.
doi: 10.1111/pcmr.12180. Epub 2013 Nov 1.

Targeting p53 in melanoma

Neil F Box  1 , Tyler O Vukmer, Tamara Terzian
Affiliations
Comment

Targeting p53 in melanoma

Neil F Box et al. Pigment Cell Melanoma Res. 2014 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Targeting molecular pathways in melanoma. The oncogenic RAS pathway is inhibited by the clinically approved BRAFV600E inhibitors zelboraf and tafinlar, while downstream MEK activity is inhibited by mekinist as a combination therapy with tafinlar. Experimental drugs that activate p53 in melanoma, including Nutlin-3a (Nut) that inhibits MDM2, the stapled peptide inhibitor of MDM4 (SAH-p53-8) and JNJ-7706621 (JNJ) that inhibits iASPP offer the possibility of developing combination therapies that target two separate pathways when used in combination with RAS pathway inhibitors [Adapted from Lu et al. (2013)].
See this image and copyright information in PMC

Comment on

References

    1. Gembarska A, Luciani F, Fedele C, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 2012;18:1247. - PMC - PubMed
    1. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systemic review and analysis of reported sequence variants. Hum. Mutat. 2007;28:588. - PubMed
    1. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:263. - PMC - PubMed
    1. Terzian T, Torchia EC, Dai D, et al. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010;23:794. - PMC - PubMed
    1. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J. A melanoma molecular disease model. PLoS ONE. 2011;6:e18257. - PMC - PubMed

MeSH terms